Pilot study evaluating intravenous amoxicillin-clavulanate as an alternative to piperacillin-tazobactam for general surgery patients.

Sarah A Drost Irina Rajakumar Elissa Rennert-May

Published in: Antimicrobial stewardship & healthcare epidemiology : ASHE (2023)

In this point-prevalence survey followed by prospective audit and feedback at 4 tertiary-care hospitals in Calgary, Alberta, Canada, we evaluated whether intravenous amoxicillin-clavulanate may be used as a narrower-spectrum alternative to intravenous piperacillin-tazobactam for patients admitted to general surgery services.

Keyphrases

high dose
tertiary care
end stage renal disease
healthcare
ejection fraction
newly diagnosed
chronic kidney disease
primary care
peritoneal dialysis
risk factors
mental health
low dose
patient reported outcomes